Dr. Yael Bar is a medical oncologist specializing in breast cancer and a senior physician at the Oncology Center of Ichilov Medical Center. Her clinical work focuses on personalized treatment strategies for patients with breast cancer at different stages of the disease.

Dr. Bar combines clinical experience with a strong background in molecular biology and precision medicine. In her daily practice, she emphasizes individualized treatment decisions based on tumor biology, disease stage, and each patient’s clinical situation.

After completing her medical degree, Dr. Bar earned a PhD in Molecular Genetics at Tel Aviv University. She later completed her oncology residency at Ichilov Medical Center.

Following her specialization, Dr. Bar completed a clinical and research fellowship in breast cancer at Massachusetts General Hospital (MGH) in Boston, one of the leading cancer centers worldwide.

Today, Dr. Bar serves as a senior physician in the Breast Cancer Unit at Ichilov Medical Center and is actively involved in clinical research in breast cancer.

She treats a wide range of breast cancer cases, including early-stage disease, locally advanced tumors, and metastatic breast cancer.

Areas of Expertise

Breast cancer treatment
Personalized breast cancer therapy
Genomic testing and precision medicine
Hormonal and biological therapies
Second opinion consultations
Patient guidance throughout treatment

Education

2010–2016: MD, Faculty of Medicine, Tel Aviv University

2004–2010: PhD in Molecular Genetics, Tel Aviv University

Residency

2016–2020: Medical Oncology Residency, Ichilov Medical Center

Fellowship

2021–2023: Clinical and Research Fellowship in Breast Cancer, Massachusetts General, Hospital (MGH), Boston, USA

Clinical Experience

2023–Present: Senior Physician, Breast Cancer Unit, Oncology Center, Ichilov Medical Center

2020–2023: Breast Cancer Clinical Fellowship, Massachusetts General Hospital, Boston

2018–Present: Sub-Investigator in Breast Cancer Clinical Trials

2016–2020: Oncology Residency, Ichilov Medical Center

Academic Activity

2023–Present: Examiner, National Oncology Board Examinations

2020–2021: Clinical Instructor, Faculty of Medicine, Tel Aviv University

Research Interests

Breast cancer
Clinical trials
Genomic testing
Precision oncology

Publications

Dr. Yael Bar’s scientific publications are available on PubMed.

Private Consultation

Dr. Yael Bar provides private consultations through Tel Aviv Medical Clinic, including:

Second opinion
Treatment review
Personalized treatment strategy
Guidance for further care

To schedule a consultation:

Phone: +972-73-374-6844
Email: [email protected]
WhatsApp: +972-52-337-3108

Frequently Asked Questions

1. When can breast cancer be treated without chemotherapy?

This is probably one of the most common questions I hear.

Today, chemotherapy is not always necessary. In some situations, we evaluate the biological characteristics of the tumor and use genomic testing to better understand the risk of recurrence.

Sometimes we find that the risk is low, and in those cases, we may consider other options such as hormonal therapy. In other situations, chemotherapy still plays an important role.

Every case is different, and decisions are made after reviewing all medical information.

2. When is hormonal therapy used in breast cancer?

Hormonal therapy is used when the tumor is hormone-sensitive. This is quite common in breast cancer.

Sometimes hormonal therapy is given after surgery to reduce the risk of recurrence. In metastatic disease, it may also be used as part of treatment.

Patients are often surprised that treatment can last several years. This is because hormonal therapy is designed for long-term disease control.

The treatment plan always depends on the individual clinical situation.

3. Does treatment always start with surgery?

Not always.

In some cases, treatment begins with systemic therapy, such as chemotherapy or targeted therapy. This is known as neoadjuvant treatment.

This approach may help shrink the tumor or provide information about how the tumor responds to treatment.

The sequence of treatment is always determined individually.

4. When is targeted therapy used?

Targeted therapy is used when the tumor has specific biological characteristics, such as HER2-positive breast cancer.

These treatments are designed to target cancer cells more precisely and are often combined with other therapies.

In recent years, targeted therapy options have expanded significantly.

5. How is metastatic breast cancer treated?

Metastatic breast cancer is a complex situation, and treatment is always individualized.

Options may include hormonal therapy, targeted therapy, chemotherapy, or other treatments. In many cases, treatment is focused on controlling the disease over time.

Patients often ask about prognosis, but every situation is different.

6. When are genomic tests used?

Genomic tests help us better understand tumor biology and assess recurrence risk.

Sometimes these tests help determine whether chemotherapy is necessary.

They are most commonly used in early-stage hormone-positive breast cancer, but not every patient needs them.

7. Can treatment be personalized?

Yes. Today, personalized medicine plays an important role in breast cancer treatment.

We consider tumor type, stage, genetic features, and overall health. This helps us choose the most appropriate treatment strategy.

There is no single solution that fits everyone.

There are no reviews yet. Be the first one to write one.